Views: 2080
Europe’s Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorization for Eltrombopag Viatris (eltrombopag), a generic medicine for the treatment of children and adults with primary immune thrombocytopenia (ITP), thrombocytopenia associated with chronic hepatitis C virus (HCV) infection, and acquired severe aplastic anemia…
Read More
Discover more from 25finz, L.L.C
Subscribe to get the latest posts sent to your email.
No comments yet. Be the first to comment!
You must be logged in to post a comment. Log in